Target intelligence / Profile preview

Mitogen-activated protein kinase signaling pathway (Ras-Raf-MEK-ERK cascade) (MAPK pathway)

Target
MAPK pathway
Molecular classification
Enzyme, Serine/threonine-protein kinase, Small GTPase
01

Overview

The Ras-Raf-MEK-ERK pathway is a central mitogen-activated protein kinase (MAPK) signaling cascade that communicates signals from surface receptors to the nucleus to regulate gene expression and cellular activity [1][2]. The pathway is activated by various extracellular stimuli, such as growth factors, which trigger the activation of the small GTPase Ras; Ras then recruits and activates Raf kinases (MAP3Ks), which in turn phosphorylate and activate MEK1/2 (MAP2Ks), ultimately leading to the activation of ERK1/2 (MAPKs) [3][4]. Dysregulation of this pathway, frequently caused by gain-of-function mutations in KRAS, NRAS, or BRAF, is a primary driver of oncogenesis in approximately 30% of human cancers, including melanoma, pancreatic, and lung adenocarcinomas [5]. Therapeutic interventions often focus on targeting specific mutated nodes within the cascade, such as BRAF or MEK, to halt pathological cell proliferation [6]. However, the therapeutic efficacy is often limited by complex feedback mechanisms and the rapid emergence of resistance through alternative signaling routes [7].

Other names
Ras/Raf/MAPK pathwayERK signaling pathwayMAPK/ERK cascadeRas-Raf-MEK-ERK signalingExtracellular signal-regulated kinase pathway
02

Mechanism of action

Small molecule inhibition of specific cascade nodes, including BRAF, MEK1/2, or mutant KRAS, to prevent the sequential phosphorylation and activation of downstream effectors that drive oncogenic growth and survival.

03

Biological functions

Cell proliferationCell differentiationSignal transductionCell survivalApoptosis
04

Disease associations

CancerRASopathies (e.g., Noonan syndrome)Cardiovascular diseaseInflammation
05

Safety considerations

Cutaneous toxicities (e.g., rash, photosensitivity)Development of secondary malignancies (e.g., cutaneous squamous cell carcinoma)Cardiotoxicity (reduced LVEF)HepatotoxicityAcquired drug resistance via bypass signaling or feedback loop activation
06

Interacting drugs

Vemurafenib

9 more in the full profile.

07

Biomarkers

BRAF V600E mutationKRAS G12C mutationNRAS mutationERK phosphorylation statusDUSP6 expression levels

Beyond the preview

Go deeper on Mitogen-activated protein kinase signaling pathway (Ras-Raf-MEK-ERK cascade) (MAPK pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase signaling pathway (Ras-Raf-MEK-ERK cascade) (MAPK pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call